Relapsed/Refractory Archives

April 29, 2022

ASH 2021: Dr. Constantine Tam on Novel BCL2 Inhibitor BGB-11417 For Patients with Relapsed/Refractory B-Cell Malignancies

Discussion of preliminary results from an ongoing phase 1 clinical trial studying the safety and efficacy of novel BCL2 inhibitor BGB-11417 alone and in combination with the next-generation BTK inhibitor zanubrutinib.

February 9, 2022

Can CAR T-Cell Therapy Truly Cure CLL/SLL?

The short answer is that it is certainly beginning to look that way for a lucky few. This month celebrated the 10th CAR-T anniversary of Doug Olson, who remains cancer-free with persistent CAR-T cells that still play WHACK-A-MOLE should any cancerous CLL cells dare to reappear.

February 6, 2022

CLL Society Education On Demand: ASH 2021 Comes to You

CLL Society brings ASH 2021 to you! The American Society of Hematology Annual Meeting had important research presented and now Drs. Anthony Mato and Brian Koffman will highlight findings that you should know when considering future treatment options.

February 3, 2022

ASH 2021: Time-Limited Venetoclax and Ibrutinib for Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Who Have Undetectable Minimal Residual Disease (uMRD) – Primary Analysis from the Randomized Phase II Vision HO141 Trial

The usual approach with most venetoclax based therapies is a “one size fits all” with all patients stopping treatment after a fixed duration, such as after one or two years of venetoclax.

January 18, 2022

ASH 2021: Subcutaneous Epcoritamab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Preliminary Results from the Epcore CLL-1 Trial

This research was presented by Dr. Arnon Kater and colleagues at the American Society for Hematology annual meeting which was held December 2021 (ASH 2021).

December 23, 2021

CAR-T Therapy for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Made Easy to Understand

CAR-T therapy is a revolutionary therapy that trains the patient’s own cells to attack their CLL/SLL. The science can be somewhat complicated and advanced, but the results can be amazing. You can learn more about CAR-T therapy in this easy-to-understand CAR-T brochure that can be viewed in this digital flipbook format

November 18, 2021

ASH 2020: Dr. Jennifer Brown on Zanubrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia (CLL/SLL) Patients with Deletion 17p

At the annual meeting of the American Society of Hematology (ASH) 2020, our own Steven Bloom interviewed Dr. Jennifer Brown, Director of the CLL Center at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. They discussed the SEQUOIA trial, which is a phase 3 trial testing

October 4, 2021

ASCO 2021 Top Pick #8: First In-Human Study of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor (BCL-2i) in Patients with Relapsed/Refractory (R/R) CLL and Other Hematologic Malignancies

In this ASCO 2021 abstract by Ailawadhi from Mayo and others, we learn of the first in human trial of a novel BCL-2 inhibitor (BCL-2i), lisaftoclax or APG-2575.

October 4, 2021

EHA 2021 Top Pick #7: Long Term Results of a Phase I/Ib Study of Ibrutinib in Combination with Umbralisib for Patients with Relapsed/Refractory (R/R) CLL (Chronic Lymphocytic Leukemia) or MCL (Mantle Cell Lymphoma)

Dr. Matt Davids of Dana Farber presented this abstract at the 2021 European Hematology Association Virtual Congress, (EHA 2021) that updated the results of combining two different oral targeted therapies that both block B-cell receptor (BCR) signaling: Ibrutinib through BTK inhibition and umbralisib, an experimental inhibitor of PI3K.

Relapsed/Refractory

ASH 2021: Dr. Constantine Tam on Novel BCL2 Inhibitor BGB-11417 For Patients with Relapsed/Refractory B-Cell Malignancies

Can CAR T-Cell Therapy Truly Cure CLL/SLL?

CLL Society Education On Demand: ASH 2021 Comes to You

ASH 2021: Time-Limited Venetoclax and Ibrutinib for Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Who Have Undetectable Minimal Residual Disease (uMRD) – Primary Analysis from the Randomized Phase II Vision HO141 Trial

ASH 2021: Subcutaneous Epcoritamab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Preliminary Results from the Epcore CLL-1 Trial

CAR-T Therapy for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Made Easy to Understand

ASH 2020: Dr. Jennifer Brown on Zanubrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia (CLL/SLL) Patients with Deletion 17p

ASCO 2021 Top Pick #8: First In-Human Study of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor (BCL-2i) in Patients with Relapsed/Refractory (R/R) CLL and Other Hematologic Malignancies

EHA 2021 Top Pick #7: Long Term Results of a Phase I/Ib Study of Ibrutinib in Combination with Umbralisib for Patients with Relapsed/Refractory (R/R) CLL (Chronic Lymphocytic Leukemia) or MCL (Mantle Cell Lymphoma)

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT US

CONTACT